In the latest session, Mersana Therapeutics Inc (NASDAQ: MRSN) closed at $5.74 down -0.52% from its previous closing price of $5.77. In other words, the price has decreased by -$0.03 from its previous closing price. On the day, 3346395 shares were traded.
Ratios:
For a deeper understanding of Mersana Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.36 and its Current Ratio is at 3.36. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.77.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wedbush on February 29, 2024, Upgraded its rating to Outperform and sets its target price to $7 from $2 previously.
On February 29, 2024, Guggenheim Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $7.
BTIG Research Upgraded its Neutral to Buy on February 29, 2024, while the target price for the stock was maintained at $6.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 16 ’24 when Protopapas Anna sold 29,399 shares for $2.71 per share. The transaction valued at 79,671 led to the insider holds 125,153 shares of the business.
Lowinger Timothy B sold 10,409 shares of MRSN for $28,208 on Jan 16 ’24. The SVP, Chief Sci.&Tech. Officer now owns 199,329 shares after completing the transaction at $2.71 per share. On Jan 16 ’24, another insider, DeSchuytner Brian, who serves as the SVP, COO & CFO of the company, sold 9,327 shares for $2.71 each. As a result, the insider received 25,276 and left with 54,511 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRSN now has a Market Capitalization of 699.92M and an Enterprise Value of 524.47M. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.89 while its Price-to-Book (P/B) ratio in mrq is 18.78. Its current Enterprise Value per Revenue stands at 14.23 whereas that against EBITDA is -3.16.
Stock Price History:
Over the past 52 weeks, MRSN has reached a high of $9.62, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is 3.39, while the 200-Day Moving Average is calculated to be 2.84.
Shares Statistics:
For the past three months, MRSN has traded an average of 2.04M shares per day and 2.87M over the past ten days. A total of 120.71M shares are outstanding, with a floating share count of 91.80M. Insiders hold about 24.32% of the company’s shares, while institutions hold 71.28% stake in the company. Shares short for MRSN as of Feb 15, 2024 were 7.1M with a Short Ratio of 3.49, compared to 7.39M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.88% and a Short% of Float of 6.40%.
Earnings Estimates
There are 8 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.19 for the current quarter, with a high estimate of -$0.13 and a low estimate of -$0.21, while EPS last year was -$0.52. The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.13 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.25 and -$0.87 for the fiscal current year, implying an average EPS of -$0.67. EPS for the following year is -$0.7, with 8 analysts recommending between -$0.33 and -$0.91.
